Enjoy complimentary customisation on priority with our Enterprise License!
The global non-alcoholic steatohepatitis (NASH) market size is estimated to grow by USD 11.22 billion at a CAGR of 40.05% between 2022 and 2027.
With increasing awareness of the link between obesity, metabolic syndrome, and non-alcoholic steatohepatitis, healthcare providers are more likely to screen and diagnose non-alcoholic steatosis patients. Higher diagnosis rates are driving demand for alcohol-free diagnostic tools and services related to steatohepatitis. Furthermore, the complex interplay between obesity metabolic syndrome and highlights the importance of a multidisciplinary approach involving hepatologists, endocrinologists, and endocrinologists. , nutritionists, and other professionals. This collaborative effort advances research and patient care. Hence, due to the increasing prevalence of obesity and metabolic syndrome, the market will witness positive growth during the forecast period.
To learn more about this market report, Request Free Sample
The market confronts the challenge of addressing liver disease aggravated by factors like chopped strand, silica sand, and soda ash in various industries. With roots possibly linked to limestone exposure, this ailment affects millions worldwide. Its impact mirrors the complexity of pipes and body panels, requiring comprehensive solutions akin to wheelhouse assemblies and front fascia repair. Innovative treatments aim to reinforce the liver's fabric, acting as a protective battery box amidst the storm of liver inflammation.
Technavio has segmented the market into Distribution Channel, Application, and Geography.
It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historic data from 2017 to 2021 besides analyzing the current market scenario.
The market share growth by the offline segment will be significant during the forecast period. Offline distribution can play a role in disseminating educational material and growing awareness about non-alcoholic Steatohepatitis. Clinics, healthcare provider offices, and community health centers can distribute leaflets, brochures, and other resources to patients to improve their understanding of non-alcoholic steatohepatitis, its risks, and how it works.
Get a glance at the market contribution of various segments View a PDF Sample
The offline segment was valued at USD 632.74 million in 2017. Offline delivery includes scheduling and performing these appointments in healthcare settings, allowing healthcare providers to assess disease progression and make necessary adjustments for a treatment plan. Offline distribution channels can facilitate interaction between patients and healthcare providers, allowing for personalized advice and support in making these changes. Therefore, factors such as diagnosis, appointment booking, and support are needed for the treatment of non-alcoholic Steatohepatitis, which will drive the growth of the offline segment in the non-alcoholic steatohepatitis (NASH) market during the forecast period.
Non-alcoholic steatohepatitis has various applications in the diagnosis and management of the disease. Diagnosis includes blood tests, imaging techniques, assessment of fibrosis, and liver biopsy. Accurate diagnosis of nonalcoholic steatohepatitis allows healthcare providers to develop personalized treatment plans and track disease progression over time. The diagnosis of nonalcoholic steatohepatitis is an integral part of larger efforts to control and treat the disease. Advances in diagnostic techniques and tools are contributing to early detection, improved patient outcomes, and overall management of nonalcoholic steatohepatitis. Hence, these reasons will drive the growth of the diagnostic segment, which will boost the growth of the market during the forecast period.
For more insights about the market share of various regions View PDF Sample now!
North America is estimated to contribute 51% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. Non-alcoholic steatohepatitis is a growing health problem in North America due to factors such as obesity, type 2 diabetes, and a sedentary lifestyle. Diagnostic methods, including blood tests, imaging technology, and noninvasive assessment of cirrhosis, are widely available and accessible in the US and Canada.
Moreover, North America has a good healthcare infrastructure, including hospitals, clinics, and diagnostic laboratories, that support the diagnosis and management of non-alcoholic steatohepatitis. Healthcare providers in the region have access to cutting-edge medical technologies and expertise that enable non-alcoholic Steatohepatitis diagnosis and comprehensive patient care, which will drive the growth of the non-alcoholic Steatohepatitis diagnosis non-alcoholic steatohepatitis market in the region during the forecast period.
Buy Now Full Report and Discover More
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 14 market companies, including:
Zydus Lifesciences Ltd.: The company offers non alcoholic steatohepatitis or NASH, such as ELF blood test to detect NASH in patients.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market witnesses significant strides in addressing liver ailments involving waist circumference, body mass index, and triglycerides as key diagnostic markers. Companies like Akero Therapeutics and Boehringer Ingelheim spearhead research into groundbreaking antidiabetes agents and bone morphogenetic medication for NASH treatment. This robust pipeline of therapies aims to tackle weight management challenges, with players like Phenex Pharmaceuticals driving innovation. Clinicalgov data underscores the pressing need, given rising healthcare expenditure linked to conditions like insulin resistance and associated symptoms such as jaundice, itchy skin, and enlarged liver. Cutting-edge diagnosis techniques, from ultrasound to liver transplant, promise enhanced outcomes for patients. There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key trends and challenges.
Rising patient engagement and education is the primary trend in the market. Patient education and engagement efforts are helping to raise awareness of non-alcoholic Steatohepatitis in the general community and those at risk. A better understanding of the risk factors, symptoms, and impacts of nonalcoholic steatohepatitis will encourage earlier diagnosis and intervention. Patient education emphasizes the importance of lifestyle changes, such as weight loss, healthy eating, and regular physical activity in managing non-alcoholic steatohepatitis.
Furthermore, attached patients are more likely to accept and maintain these changes, leading to better disease control. Informed patients may be willing to participate in clinical trials of experimental alcohol-free treatments for steatohepatitis. Patient involvement initiatives promote a sense of community and support among people living with non-alcoholic Steatohepatitis. Therefore, increasing patient participation and education will propel the growth of the target market during the forecast period.
The lack of approved therapies is a challenge that affects the growth of the market. The lack of approved treatments for non-alcoholic steatohepatitis complicates the design and conduct of clinical trials. Developing successful trials requires identifying meaningful endpoints and demonstrating the efficacy and safety of potential treatments without establishing standards. Patients with nonalcoholic steatohepatitis may not have access to targeted treatments that can help them control the disease.
Moreover, the absence of approved therapies motivates researchers and pharmaceutical companies to innovate in clinical trial design, endpoints, and strategies to demonstrate the effectiveness of investigational drugs. Thus, the absence of approved therapies is a significant challenge that impedes the growth of the market during the forecast period.
Buy Now Full Report and Discover More
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market forecast report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Market Customer Landscape
The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2023 to 2027, as well as historical data from 2017 to 2022 for the following segments.
Steatohepatitis, characterized by nonalcoholic fatty liver damage, poses significant health risks such as fatigue, weakness, and abdominal discomfort. Promising developments in treatment include drugs like cilofexor and Lanifibranor, both panPPAR agonists, under development by AbbVie. These drugs target symptoms like fluid accumulation and pain, aiming to improve liver function and alleviate symptoms associated with the disease. Lifestyle modifications play a crucial role alongside medication, with a focus on addressing genetic predispositions and promoting overall wellbeing. Transient elastography aids in monitoring disease progression, offering insights into blood pressure regulation and the risk of cardiovascular diseases and cancer. These advancements signify a shift towards targeted therapies addressing the root cause of the disease for improved patient outcomes and increased lifespan.
Market Scope |
|
Report Coverage |
Details |
Page number |
146 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 40.05% |
Market growth 2023-2027 |
USD 11.22 billion |
Market structure |
Concentrated |
YoY growth 2022-2023(%) |
37.32 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 51% |
Key countries |
US, Canada, Germany, UK, and China |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
AstraZeneca Plc, BioPredictive S.A.S, Cirius Therapeutics, Enzo Biochem Inc., GENFIT SA, Gilead Sciences Inc., GlaxoSmithKline Plc, Inventiva S.A., Madrigal Pharmaceuticals Inc., Novo Nordisk AS, Prometheus Laboratories, Siemens Healthineers AG, Zydus Lifesciences Ltd., and Intercept Pharmaceuticals Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
View Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Distribution Channel
7 Market Segmentation by Application
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.